CrushSCI.com
115.1平均天数
97.5中位天数
36最短天数
230最长天数
3322025发文量

Paper Review Records

全部论文审稿周期

20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

65 天

Antibody–drug conjugates combined with immune checkpoint inhibitors in cancer: mechanisms, clinical evidence, and translational challenges

作者
Yangchun Du; Zhaozhong Tu; Min Ling; Peng Luo; Lijun Li; Yizhao Luo; Zhiwei Ma展开收起
作者单位
1. Department of Organ Transplantation, Sichuan Academy of Medical Sciences, University of Electronic Science and Technology of China, Sichuan Provincial People’s Hospital, Chengdu, China; 2. Center of Anesthesiology and Operating Rooms, Sichuan Academy of Medical Sciences, University of Electronic Science and Technology of China, Sichuan Provincial People’s Hospital, Chengdu, China; 3. Department of Oncology, Southern Medical University, Zhujiang Hospital, Guangzhou, China; 4. Shantou University Medical College, Shantou, China; 5. Department of Urology, Sichuan Academy of Medical Sciences, University of Electronic Science and Technology of China, Sichuan Provincial People’s Hospital, Chengdu, China展开收起
PDF源文件 DOI 网页
111 天

Lactate metabolism and epigenetic reprogramming in cancer: beyond energy metabolism to chromatin dynamics

作者
Sitong Li; Jintian Zhang; Feng Zhao; Changjing Cai; Namei Li; Kai Liu展开收起
作者单位
1. Department of Oncology, Xiangya Hospital, Central South University, Changsha, China; 2. Xiangya School of Medicine, Central South University, Changsha, China; 3. Department of Cardiology, Beijing Hospital, Peking Union Medical College Hospital, Beijing, China; 4. Department of Neurology, Peking University First Hospital, Beijing, China; 5. National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Central South University, Changsha, China; 6. Department of Cardiovascular Surgery, Xiangya Hospital, Central South University, Changsha, China; 7. Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China; 8. Transplantation Center, The Third Xiangya Hospital, Central South University, Changsha, China; 9. NHC key laboratory of translational research on transplantation medicine, Changsha, China展开收起
PDF源文件 DOI 网页
67 天

Lactate and lactylation in cancer: mechanistic insights and therapeutic implications

作者
Ting Liu; Chen Huang; Chenliang Zhang; Yuyuan Xiong; Xudong Wang; Zhenyu Ding展开收起
作者单位
1. Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; 2. Health Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China; 3. Division of Abdominal Tumor Multimodality Treatment, Cancer Center and Laboratory of Abdominal Tumor Immunology and Microenvironment, West China Hospital, Sichuan University, Chengdu, China; 4. Department of Medical Engineering Technology, West China Hospital, Sichuan University, Chengdu, China; 5. Department of Orthopedics, Junlian County People’s Hospital, Sichuan, China展开收起
PDF源文件 DOI 网页
140 天

From molecular bridges to therapeutic targets: the pivotal role of liquid-liquid phase separation in tumors and new frontiers in targeted therapy

作者
Yuxiang Chen; Yining Sun; Feifan Chen; Binyang Luo; Zhu Wang; Yuzhi Liu; Kai Deng; Jinlin Yang展开收起
作者单位
1. Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China; 2. Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital of Sichuan University, Chengdu, China展开收起
PDF源文件 DOI 网页
177 天

The evolution of “magic bullets”: precision guidance, clinical challenges, and efficacy enhancement of antibody-drug conjugates in solid tumors

作者
Ying Li; Junfeng Zhao; Jiaxuan Chen; Yifei Yan; Chen Zhou; Wenjie Chen; Yali Xu; Chao Tu; Yintao Li展开收起
作者单位
1. Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; 2. Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; 3. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; 4. Department of Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; 5. Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China; 6. Department of Pathology, Shandong Provincial Hospital Affiliated with Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China; 7. Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, China; 8. Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, China; 9. Hunan Engineering Research Center of AI Medical Equipment, The Second Xiangya Hospital of Central South University, Changsha, China; 10. Department of Medical Oncology, Peking University First Hospital, Peking University, Beijing, China展开收起
PDF源文件 DOI 网页
195 天

Increasing cancer stemness drives prostate cancer progression, plasticity, therapy resistance and poor patient survival

作者
Xiaozhuo Liu; Anmbreen Jamroze; Eduardo Cortes; Yibing Ji; Kathy Zhao; Faming Zhao; Julian Ho; Yang Liu; Elai Davicioni; Shan Wu; Wen Jess Li; Felix Y. Feng; Joshi J. Alumkal; Daniel E. Spratt; Christopher J. Sweeney; Han Yu; Qiang Hu; Cheng Zou; Dingxiao Zhang; Kevin Lin; Yue Lu; Gurkamal Chatta; Kent L. Nastiuk; David W. Goodrich; Kiera Rycaj; Jason S. Kirk; Igor Puzanov; Zheng Xia; Song Liu; Jianmin Wang; Dean G. Tang展开收起
作者单位
1. Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, USA; 2. Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, USA; 3. Department of Biostatistics, University at Buffalo, Buffalo, USA; 4. Veracyte Inc, San Diego, USA; 5. Department of Biomedical Engineering, The University of Texas at Austin, Austin, USA; 6. Experimental Therapeutics Graduate Program, University at Buffalo and Roswell Park Comprehensive Cancer Center, Buffalo, USA; 7. Department of Radiation Oncology, University of California, San Francisco, USA; 8. Department of Internal Medicine, Department of Hematology and Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, USA; 9. University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, USA; 10. South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia; 11. School of Biomedical Sciences, Hunan University, Changsha, China; 12. Department of Epigenetics and Molecular Carcinogenesis, the University of Texas M.D Anderson Cancer Center, Houston, USA; 13. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, USA; 14. Department of Cancer Genetics, Roswell Park Comprehensive Cancer Center, Buffalo, USA展开收起
PDF源文件 DOI 网页

FAQ

Molecular Cancer审稿要多久?

截至2026-11-18,CrushSCI 收录了 Molecular Cancer 的 20 篇完整审稿记录。最快一篇从收稿到录用用了 36 天(Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation,2026-04-13 收稿,2026-05-19 录用),最慢一篇用了 230 天;平均 115.1 天,中位数 97.5 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。